EP1435912A1 - Neue stabile kristallform von n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanin und herstellungsverfahren - Google Patents

Neue stabile kristallform von n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanin und herstellungsverfahren

Info

Publication number
EP1435912A1
EP1435912A1 EP01978760A EP01978760A EP1435912A1 EP 1435912 A1 EP1435912 A1 EP 1435912A1 EP 01978760 A EP01978760 A EP 01978760A EP 01978760 A EP01978760 A EP 01978760A EP 1435912 A1 EP1435912 A1 EP 1435912A1
Authority
EP
European Patent Office
Prior art keywords
trans
phenylalanine
crystal form
solvent
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01978760A
Other languages
English (en)
French (fr)
Other versions
EP1435912A4 (de
Inventor
Vrajesh Shah
Anurag Hitkari
Keshav Deo
Srinivasan Rengaraju
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alembic Ltd
Original Assignee
Alembic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN872MU2001 external-priority patent/IN191354B/en
Application filed by Alembic Ltd filed Critical Alembic Ltd
Publication of EP1435912A1 publication Critical patent/EP1435912A1/de
Publication of EP1435912A4 publication Critical patent/EP1435912A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups

Definitions

  • the present invention relates to novel stable crystal form of N-(trans-4- isopropylcyclohexylcarbonyl)-D-phenylalanine.
  • the Crystals of N-(trans-4- isopropylcyclohexylcarbonyl)-D-phenylalanine have different melting point, infra red spectrum and X-ray diffraction patterns from previously known forms, " B- Type” and " H-Type" of the compound .
  • N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine is disclosed in Japanese Patent Application Laid Open No. 63-54321 (equivalent to EP-A- 196222 and US 4,816,484) and in J. Med. Chem. 32, 1436-41 ( 1989 ).
  • "The Japanese application describes how the compound may be crystallized from aqueous methanol to yield crystals having a melting point of 129° to 130° C. These crystals are in a crystalline form referred to herein as "B-type”.
  • An infra red absorption spectrum and powder X-ray diffraction pattern are disclosed in the US patent no. 5463116 Oct. 31 1995".
  • N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine of formula (1) is a known substance having therapeutic utility in depressing blood glucose levels.
  • the present inventors have made a novel stable crystalline form of N-(trans-4- isopropylcyclohexylcarbonyl)-D-phenylalanine.
  • the crystals as formed by the present invention hereinafter designated as the "AL-type" crystals of N-(trans-4- isopropylcyclohexyl carbonyl)-D-phenylalanine are substantially stable to the physical grinding. Such crystals are therefore more suitable for use in medicines than the existing crystals of N-(trans-4- isopropylcyclohexyl carbonyl)-D-phenylalanine
  • the new form is different than previously known disclosed forms : so called “B- type” and "H-type".
  • the inventors have designated the new stable crystalline form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine as "AL-type”.
  • N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds A new class of oral hypoglycemic agents. 2.
  • the " AL-type" Crystals of N-(trans-4-isopropylcyclohexyl carbonyl)-D- phenylalanine may be formed by crystallization from solution, the crystallization from solution taking place at a temperature between 30°C and the boiling point of the solvent.
  • the crystals thus formed generally comprise enhanced amounts of " AL-type" crystals relative to the starting N-(trans-4-isopropylcyclohexylcarbonyl)-D- phenylalanine.
  • crystallization at about 30 °C may be performed in several ways as will be apparent to those of skill in the art.
  • -(trans-4-isopropylcyclohexylcarbonyl)-D- phenylalanine " B-type" crystals may be dissolved in a solvent in which it is readily soluble at higher temperature but in which it is only sparingly soluble at lower temperatures.
  • Solvents which are suitable for use in this invention may be selected from the group comprising dimethyl formamide, dimethylacetamide and acetonitrile.
  • the solvent is acetonitrile.
  • the dissolution volume of the solvent is preferably from 8 to 60 vol % of the solvent.
  • the temperature of the solution is preferably 55° C to 75°C.
  • the new crystals were obtained from the solution by filtration or centrifuging and then dried at a temperature in the range 50° C to 90°C
  • FIGURE 1 Shows differential scanning calorimeter (DSC) of "AL-type" crystal form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylaIanine.
  • FIGURE. 2 Shows a powder X-ray diffraction pattern of "AL-type" crystal form of N-(trans-4-isopropyIcyclohexylcarbonyl)-D-phenylalanine in accordance with the present invention.
  • FIGURE. 3 Shows an infra red absorption spectrum of "AL-type" crystal form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine in accordance with the present invention.
  • FIGURE 4 Shows a crystals photograph of "AL-type" form of N-(trans-4- isopropylcyclohexylcarbonyl)-D-phenylalanine in accordance with the present invention.
  • FIGURE. 5 Shows a crystals photograph of "H-type” form of N-(trans-4- isopropy!cyclohexylcarbonyI)-D-phenylalanine.
  • FIGURE 6 Shows a crystals photograph of "B-type” form of N-(trans-4- isopropylcyclohexylcarbonyl)-D-phenylalanine.
  • the present invention provides a stable "AL- type” crystalline form of N-(trans- 4-isopropylcyclohexyl carbonyl)-D-phenylalanine.
  • the various examples of the physical properties of the "AL-type" crystal form of N-(trans-4- isopropylcyclohexyl carbonyl)-D-phenylalanine are as follows.
  • the inventors have measured the melting point of new "AL-type" crystals of N- (trans-4-isopropylcyclohexyl carbonyl)-D-phenylalanine and found it to be in the range of 174° to 178° C.
  • the powder X-ray diffraction patterns of new " AL-type” crystals of N-(trans-4- isopropylcyclohexyl carbonyl)-D-phenylalanine as shown in Anex-2 is obtained by using a Philips PW1700 powder diffractometer and a scan speed of 0.05.degree./sec.
  • the observed powder X-ray diffraction patterns of new " AL- type” crystals is different than the disclosed X-ray diffraction patterns in patent US 5463116 for " B-type” & " H-type” crystals of N-(trans-4-isopropyIcyclohexyl carbonyl)-D-phenylalanine.
  • the new "AL-type" crystals of N-(trans-4- isopropylcyclohexyl carbonyl)-D- phenylalanine are preferably substantially stable to the physical grinding. Stability to grinding may be assessed by measurement of physical property before and after grinding. Where the physical property remains substantially unchanged. Suitable physical properties for measurement includes melting point, differential scanning calorimeter and infra red absorption spectrum.
  • the " AL-type" Crystals of N-(trans-4-isopropylcyclohexyl carbonyl)-D- phenylalanine may be formed by crystallization from solution, the crystallization from solution taking place at a temperature between 30°C and the boiling point of the solvent.
  • the crystals thus formed generally comprise enhanced amounts of " AL-type” crystals relative to the starting N-(trans-4- isopropylcyclohexylcarbonyl)-D-phenylalanine.
  • the crystallization at about 30 °C may be performed in several ways as will be apparent to those of skill in the art.
  • -(trans-4-isopropylcyclohexylcarbonyl)-D- phenylalanine " B-type" crystals may be dissolved in a solvent in which it is readily soluble at higher temperature but in which it is only sparingly soluble at lower temperatures.
  • Solvents which are suitable for use in this invention include dimethyl formamide, dimethylacetamide and acetonitrile. .
  • a preferred solvent is acetonitrile.
  • the dissolution volume of the solvent is preferably from 8 to 60 vol % of the solvent.
  • the temperature of the solution is preferably 55° C to 75°C.
  • the new crystals were obtained from the solution by filtration or centrifuging and then dried at a temperature in the range 50° C to 90°C.
  • N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine " B-type" (5 g) was dissolved in acetonitrile 60 ml. at 55 - 60° C. The solution was cooled with stirring.
  • "AL-type" crystal form of N-(trans-4-isopropylcyclohexylcarbonyl)-D- phenylalanine (0.1 g) prepared in Example 1 were added at a temperature of 30 - 38° C and the solution was cooled further to 25° C. The crystals were filtered and dried at 70-80° C. overnight and at reduced pressure. 1.5 g of dry crystals were obtained. The crystals had a melting-point of 174° to 178° C.
  • the powder X-ray diffraction pattern and the infra-red absorption spectrum enabled the crystals to be identified as "AL-type".

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP01978760A 2001-09-12 2001-11-05 Neue stabile kristallform von n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanin und herstellungsverfahren Withdrawn EP1435912A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
INMU08722001 2001-09-12
INMU08712001 2001-09-12
IN871MU2001 2001-09-12
IN872MU2001 IN191354B (de) 2001-09-12 2001-09-12
PCT/IB2001/002080 WO2003022251A1 (en) 2001-09-12 2001-11-05 Novel stable crystal form of n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanine and process of preparation

Publications (2)

Publication Number Publication Date
EP1435912A1 true EP1435912A1 (de) 2004-07-14
EP1435912A4 EP1435912A4 (de) 2005-03-30

Family

ID=26324909

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01978760A Withdrawn EP1435912A4 (de) 2001-09-12 2001-11-05 Neue stabile kristallform von n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanin und herstellungsverfahren

Country Status (2)

Country Link
EP (1) EP1435912A4 (de)
WO (1) WO2003022251A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304366C (zh) 2002-04-15 2007-03-14 诺瓦提斯公司 N－(反式－4－异丙基环己基羰基)－d－苯丙氨酸的晶形
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
IL166308A0 (en) * 2002-07-18 2006-01-15 Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
AU2003262928A1 (en) * 2002-08-28 2004-03-19 Dr. Reddy's Laboratories Limited Crystalline form of nateglinide and process for preparation thereof
JP2007528858A (ja) * 2004-05-07 2007-10-18 テバ ファーマシューティカル インダストリーズ リミティド ナテグリニドの多形形態

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526171A2 (de) * 1991-07-30 1993-02-03 Ajinomoto Co., Inc. Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526171A2 (de) * 1991-07-30 1993-02-03 Ajinomoto Co., Inc. Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LI, GANG ET AL: "A new crystal structure in nateglinide found by X-ray powder diffraction" XP002315303 retrieved from STN Database accession no. 2001:844448 & YAOWU FENXI ZAZHI , 21(5), 342-344 CODEN: YFZADL; ISSN: 0254-1793, 2001, *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LI, GANG ET AL: "New crystal form of nateglinide" XP000224976 retrieved from STN Database accession no. 2001:625224 & YAOXUE XUEBAO , 36(7), 532-534 CODEN: YHHPAL; ISSN: 0513-4870, 2001, *
See also references of WO03022251A1 *

Also Published As

Publication number Publication date
WO2003022251A1 (en) 2003-03-20
EP1435912A4 (de) 2005-03-30

Similar Documents

Publication Publication Date Title
RU2198169C2 (ru) Полиморфные формы 2-(3-циан-4-изобутилоксифенил)-4-метил-5-тиазолкарбоновой кислоты и способы их получения
RU2631321C2 (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
US8217061B2 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
US5463116A (en) Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JP5305248B2 (ja) 新規ナテグリニド結晶
JP6554617B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミン塩の新規な結晶形
TWI362382B (en) Process for preparing a pharmaceutical composition comprising ritonavir
WO2003022251A1 (en) Novel stable crystal form of n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanine and process of preparation
JP3726291B2 (ja) 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
AU2017304887A1 (en) Polymorphic forms of belinostat and processes for preparation thereof
KR20000070735A (ko) 역-용매를 사용한 역전사효소 억제제의 결정화 방법
US20090253933A1 (en) Nateglinide crystals
MX2009001770A (es) Sales de 5-(l(s)-amino-2-hidroxietil)-n-[(2.4-difluorofenil)-metil ]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida.
KR19980064286A (ko) 다형태를 갖는 독사조신 메실레이트의 새로운 형태(제 1형)
US6133269A (en) Polymorphic form of doxazosin mesylate (form II)
JP4657393B2 (ja) ドキサゾシン・メシレートの新規な形態ｉｉｉ
CN107344934B (zh) 药物活性物质的固体形式
JP7068411B2 (ja) ヘキサデシルトレプロスチニル結晶及びその製造方法
CN106432253B (zh) 一种维帕他韦新晶型及其制备方法
CN107698563B (zh) 制备马来酸来那替尼晶型的方法
RU2523279C2 (ru) Новая кристаллическая форма соединения трициклического бензопирана и способ его производства
CN112679428A (zh) 罗沙司他新晶型及其制备方法
JP7051968B2 (ja) オキサゾール化合物結晶
JP7326295B2 (ja) オキサゾール化合物結晶
CN110964017A (zh) 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040408

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050607